[Towards a new vaccine economy?]

Area of Science:

• Vaccinology
• Infectious Disease Control
• Biotechnology

Context:

• The global vaccine market experienced stability until the mid-1980s, following early successes like the polio vaccine.
• Significant market shifts began with the introduction of the hepatitis B vaccine in 1984.
• The market is characterized by consolidation among major pharmaceutical companies and intense competition for smaller firms.

Purpose:

• To analyze the evolution and future trends of the global vaccine market.
• To highlight the impact of technological innovations on vaccine development and supply.
• To identify key players and market dynamics in the vaccine industry.

Summary:

• Technological advancements, particularly in molecular biology and genetic engineering, have spurred the development of novel vaccines, such as recombinant hepatitis B and conjugate vaccines for meningitis.
• The market has seen increased concentration among large pharmaceutical companies, including Pasteur Mérieux, SmithKline Beecham, and Merck & Co.
• Despite market consolidation, medium and small companies face challenges in maintaining long-term viability amidst rapidly growing global demand.

Impact:

• The development of new vaccines against diseases like hepatitis A, herpes, and Lyme disease is anticipated.
• Innovations are projected to double the world vaccine market demand by the year 2000.
• The success of vaccines like hepatitis B, with annual sales of $600 million, demonstrates the significant economic and public health impact of advanced vaccinology.